Wha-Bin Im

This inventor holds 37 USPTO granted patents and 13 published patent applications, plus 1 CIPO patent and 1 EPO patent, primarily in Sphingosine-1 Phosphate Modulators. Top assignee: Allergan, Inc.. Active years: 2009-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Wha-Bin Im. Retrieved from https://idiyas.com/inventor/wha-bin-im-s0v499oa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 37 (Patent Applications = 13)

% Patents Active = 27.0

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 7)

Average Co-Inventor Count = 4.0

ph-index = 3

Forward Citations = 21(Granted Patents)

Company Filing History:

37 out of 2,287

Allergan, Inc.

patents

Years Active: 2009-2017

Loading Chart...

Areas of Expertise:

Sphingosine-1 Phosphate

Inflammatory Bowel Disease

Glaucoma Treatment

Azetidine Derivatives

Oxadiazole Derivatives

Prodrugs

Combination Therapy

Therapeutic Agents

Central Corneal Thickening

Phenoxy Derivatives

Alkyne Derivatives

Pyridine Derivatives

37 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9637467 - Treatment of inflammatory bowel disease (2017-05-02),

2. 9427401 - Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes (2016-08-30),

3. 9156810 - Treatment of inflammatory bowel disease (2015-10-13),

4. 9120784 - 1,3,4-oxadiazoles-2-thio azetidine derivatives as sphingosine-1 phosphate receptors modulators (2015-09-01),

5. 9024042 - Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes (2015-05-05),

6. 9000016 - 1,3,4-Oxadiazoles-2-thio derivatives as sphingosine-1 phosphate receptors modulators (2015-04-07),

7. 8993553 - Azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators (2015-03-31),

8. 8957051 - Bicyclic 1, 2, 4-oxadiazoles derivatives as sphingosine-1 phosphate receptors modulators (2015-02-17),

9. 8906899 - Azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators (2014-12-09),

10. 8859598 - 1, 2, 4-oxadiazoles azetidine derivatives as sphingosine-1 phosphate receptors modulators (2014-10-14),

11. 8846729 - 2-thio-1,3,4-oxadiazoles azetidine derivatives as sphingosine-1 phosphate receptors modulators (2014-09-30),

12. 8846728 - Oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators (2014-09-30),

13. 8754122 - Geminal dialkyl prostanoids (2014-06-17),

14. 8754066 - Phenoxy derivatives as sphingosine 1-phosphate (S1P) receptor modulators (2014-06-17),

15. 8735433 - Aryl oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators (2014-05-27),

Title: Innovations by Wha-Bin Im: A Focus on Medical Advancements

Introduction

Wha-Bin Im, an esteemed inventor based in Irvine, CA, has made significant contributions to the field of pharmaceuticals, holding an impressive portfolio of 37 patents. His work focuses primarily on innovative treatments for various medical conditions, showcasing his dedication to improving patient care.

Latest Patents

Among the latest patents attributed to Wha-Bin Im is a method for treating inflammatory bowel disease. This patent outlines a novel approach that involves administering a specific compound to mammals suffering from this condition. The compound is characterized by a unique structure, allowing for targeted therapeutic effects. Additionally, he has developed compositions and methods aimed at treating glaucoma, particularly through the use of hydrophilic ester prodrugs of beta-chlorocyclopentanes. These innovations are critical in reducing central corneal thickening, further demonstrating his commitment to enhancing ocular health.

Career Highlights

Wha-Bin Im is currently affiliated with Allergan, Inc., a leading global pharmaceutical company known for its focus on eye care and medical aesthetics. His role within Allergan has enabled him to push the boundaries of research and development, as evidenced by his substantial patent portfolio. His inventive spirit and expertise in the pharmaceutical sector have established him as a key player in the field of medical innovation.

Collaborations

Throughout his career, Wha-Bin Im has collaborated with notable professionals such as Ken Chow and Wenkui Ken Fang. These collaborations highlight the importance of teamwork in advancing medical technologies and fostering innovative ideas that can lead to groundbreaking treatments.

Conclusion

Wha-Bin Im's contributions to the field of medicine through his patents are a testament to his ingenuity and commitment to improving health outcomes. With a robust portfolio and ongoing collaborations, he continues to be at the forefront of innovation, making a significant impact on patient care and treatment methodologies.

Profile summary based on public USPTO records.